somaxon pharmaceuticals
Investor Relations
Home > Investor Relations

Investor Relations

Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products for the treatment of diseases and disorders in the central nervous system therapeutic area. Somaxon's lead product candidate is Silenor® (doxepin) for the treatment of insomnia.

Latest News

Jan 27, 2010
Somaxon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference (pdf)

Jan 21, 2010
SOMAXON PROVIDES UPDATE ON NEW DRUG APPLICATION FOR SILENOR® FOR THE TREATMENT OF INSOMNIA (pdf)

Webcasts

Feb 8, 2010 at 9:30 AM ET
12th Annual BIO CEO & Investor Conference

 

Stock Quote


SOMX(Common Stock)
Last Trade $2.68
Change down 0.29
Exchange NASDAQ
Volume 2,407,900

02/08/10 3:59 PM ET
Minimum 20 Minute Delay.
Refresh Quote.

Annual Reports





Join Our Mailing List

Please join our mailing list if you wish to receive news regarding Somaxon and its products.